About Fulcrum Therapeutics, Inc. - Common Stock (FULC)
Fulcrum Therapeutics Inc is a biopharmaceutical company focused on developing innovative therapies for serious genetic diseases. The company leverages its proprietary drug discovery platform to address the underlying causes of these conditions, particularly in diseases caused by gene mutations and epigenetic factors. By targeting specific pathways and mechanisms, Fulcrum aims to create treatments that significantly improve the quality of life for patients affected by these challenging disorders. Its commitment to scientific innovation and collaboration with the medical community drives the advancement of potential therapies from preclinical stages through clinical development. Read More
Fulcrum Therapeutics (NASDAQ:FULC) has entered into an all-stock merger agreement with privately held Slate Medicines, a migraine-focused biotechnology company, in a transaction expected to close in the fourth quarter of 2026, subject to stockholder approval and customary closing conditions.
Alex S
Halper Sadeh LLC, an investor rights law firm, is investigating the merger of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) and Slate Medicines, Inc. Upon closing of the proposed transaction, Fulcrum shareholders are expected to own 5.0% of the combined company.
NEW YORK, NY - June 20, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. (“Fulcrum Therapeutics” or the “Company”) (NASDAQ: FULC).
NEW YORK, NY - June 19, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. (“Fulcrum Therapeutics” or the “Company”) (NASDAQ: FULC).
NEW YORK, NY - June 18, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. (“Fulcrum Therapeutics” or the “Company”) (NASDAQ: FULC).
NEW YORK, NY - June 17, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. (“Fulcrum Therapeutics” or the “Company”) (NASDAQ: FULC).
NEW YORK, NY - June 16, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. (“Fulcrum Therapeutics” or the “Company”) (NASDAQ: FULC).
NEW YORK, NY - June 10, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. (“Fulcrum Therapeutics” or the “Company”) (NASDAQ: FULC).
